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The methylation at the α-N-terminal amines of proteins that start with a
canonical motif X-P-K (X=A/P/S) has been a known modification for nearly four decades.
In 2010, protein α-N-terminal methyltransferase 1 (NTMT1/NRMT1) was identified as
the first enzyme responsible for this modification. NTMT2 was discovered as a second
member belonging to this family, but it was reported as a mono-methylase. The
identification of RCC1, retinoblastoma (Rb) protein, centromere protein-A/B (CENP-A/B),
and DNA damaged-binding protein 2 (DDB2) as new NTMT1 substrates revealed
NTMT1’s biological significance in mitosis, cell-cycle regulation, centromere formation,

and damaged DNA repair, respectively. Although significant progress had been made, a
clear understanding of how NTMT1 recognizes substrates remains to be determined.
Also, there is no specific small molecule inhibitor for NTMT1.
To fill these gaps, we first established a fluorescence-based assay for kinetic
characterization of NTMT1. Subsequently, ternary complex crystal structures of NTMT1
were obtained to illustrate the structural basis for enzyme-substrate interactions. The
structures of the enzyme-substrate complex coupled with mutagenesis, binding, and
enzymatic studies demonstrated the key elements involved in interaction with its
substrates. In the meantime, we utilized computational studies and fluorescence assays
for novel small molecule discovery. Lastly, we closely monitored the substrates’
methylation progression by NTMT1 and NTMT2 in parallel using a MALDI-MS based
assay.
Our results indicated that NTMT1 follows a Bi-Bi mechanism, and its
methylation proceeds in a distributive pattern. Furthermore, NTMT1 was identified has
broad substrate specificity beyond its canonical motif X-P-K (X=A/P/S), since X can be
any amino acid except D/E and the third amino acids can also be R. We had also
discovered an inhibitor that targets the substrate binding site of NTMT1 with IC 50 = 7 µM.
Lastly, our methylation progression studies has demonstrated that NTMT2 can also di-,
tri-methylate certain substrates although its methylation rate is lower than NTMT1.
Overall, this project has laid the foundation for further investigation of Nterminal methylation in terms of functions, mechanisms, and inhibitor design.

1. Introduction
Post translational modification (PTM) is a biochemical process utilized by
nature to alter the “chemical makeup” of various proteins and molecules.1 In this
process, substrates are covalently modified through “addition” or “removal” of different
functional groups including acetylation, phosphorylation and methylation.2-4 PTM is
believed to be “nature’s unique way to escape from genetic imprisonment.” 2 So far,
about 400 types of PTMs have been discovered, and more than 90,000 modifications
have been identified. PTM has emerged as a major regulatory mechanism in different
life forms through changes in subcellular localization, enzymatic activities, protein
stability, and interactions with other proteins or molecules.1
PTMs are generally catalyzed by two types of enzymes. One type is referred
as a “writer” such as the methyltransferases, acetyltransferases and kinases that add
chemical groups to substrates. The other type is called an “eraser” such as the
demethylase, deacetylase, and phosphatase that remove corresponding modifications
from substrates.1,

3

Generally, each PTM on each specific residue may represent a

specific functional modification. In addition, combination of different types of PTM on the
same substrate, leads to a diversified mechanism to regulate protein structures and
functions.3, 4 The histone code is a well-known example to illustrate such complexity of
PTMs on its substrate, as the patterns of PTMs on the flexible histone tails regulate
nucleosome assembly and chromatin structure.5 Additionally, “reader” proteins that
1

recognize specific PTMs serve as a third dimension of regulation to guide and
determine the biological outcome of certain PTMs.5
1.1 Acetylation
Acetylation refers to the covalent addition of an acetyl group to a protein. 6, 7
This modification was first identified on the epsilon amino group of a Lys residue of the
histone protein in 1963.5 Therefore, the first identified enzyme responsible for
acetylation is named histone acetyltransferase (HAT).8, 9 Recent studies discovered that
acetylation can occur on many non-histone proteins such as tumor suppressor p53,
transcriptional repressor protein YY1, high mobility group proteins, estrogen receptor α,
hypoxia – inducible factor α and nuclear factor kappa-light-chain-enhancer of activated
B cells.10-14 Hence, HATs have been renamed as lysine acetyltransferases (KATs) to
reflect their ability to install an acetyl group on the side chain of a lysine residue of nonhistone proteins.5,

15

On the other hand, lysine deacetylases (KDACs/HDACs) can

remove the acetyl group from the side chain of lysine.15 As interplays between KAT and
KDAC regulate gene expression (Figure1), both KATs and KDACs are important
epigenetic drug targets for various diseases including cancer, cardiovascular diseases,
inflammation, and neurodegenerative diseases.8

2

Figure 1. Protein acetylation and deacetylation.
Acetylation plays an important role in transcriptional activities, protein stability,
and protein-protein interactions.7, 16 Acetylation on the epsilon amino group of the lysine
residue under physiological conditions modifies the overall electrostatic properties of the
protein.6,

9

Specifically, acetylation is one of the key epigenetic modifications that

regulates chromatin structure because acetylated chromatin normally results in an open
form and is thus accessible to various transcription factors (Figure 2).5, 17, 18

3

A

Acetylated chromatin

Gene on

Open and transcriptionally active

B

Deacetylated chromatin

Gene off

Compact and transcriptionally repressed
Figure 2. Acetylation and deacetylation of chromatin regulate gene expression.
A. Acetylation (red sphere) on chromatins inhibits the folding of nucleosome arrays,
which results in an open form to facilitate the access of transcription factors. B.
Deacetylation of chromatins results in chromatin condensation, which in turn prohibits
access of transcription factors.5

1.2 Phosphorylation
Phosphorylation refers to the addition of a phosphate group that is provided by
a co-factor called adenosine triphosphate (ATP) to serine, threonine, and tyrosine
residues on its target molecules.19-25 Protein kinases are the enzymes responsible for
phosphorylation modification.26-28 Based on the residue of phosphorylated, kinases are
divided into two categories: protein serine/threonine kinases and protein tyrosine
kinases.19, 29

4

Figure 3. Phosphorylation modification.
Phosphorylation is intensively involved in regulating protein conformation
activities and signal transduction.19, 30 Under physiological conditions, the phosphoryl
group is double negatively charged (Figure 3), and is frequently observed to have
interactions with an Arg sidechain.19 This interaction is known to stabilize the
conformational state of a protein. Enzymes can be activated through phosphorylation
through allosteric conformational

changes.19 One such example is glycogen

phosphorylase, which exists in at least two functional states: the T (tense) state (a less
active state), and the R (relaxed) state (a more actively state). The equilibrium between
these two states is controlled by a phosphorylation switch. 23 Phosphorylation can also
inhibit enzyme activity through steric blockage of substrate recognition site using
phosphate group.30 Additionally, in some cases, protein kinases may require
phosphorylation at an allosteric site to induce a conformational change to create an
active site for the subsequent phosphorylation.31

5

1.3 Methylation.
Methylation is a biochemical process of covalent addition of methyl groups to
protein substrates.32-34 The history of methylation can be traced back to early 1960s with
the discovery of N-methyl-lysine in the flagella protein of S. typhimurium. During an
investigation of the origin of N-methyl-lysine residues in histone, N-dimethy-lysine was
identified in 1967 and followed by the identification of N-trimethyl-lysine in 1968.32, 35, 36
Those discoveries initiated the pursuit of the enzyme responsible for such methylation
reactions.37 Interestingly, instead of discovering the protein responsible for lysine
methylation, the first identified methylation protein was responsible for arginine
methylation and is now known as protein arginine methyltransferse (PRMT).32 Since the
introduction of modern biochemical techniques in 1995, many various types of
methylation proteins have been discovered and their important biological functions have
been revealed in signal transduction, gene regulation, biosynthesis, and protein repair. 38,
39

Because of its significance, methylation has drawn attention and has become a

rapidly expanding field.32
Methyltransferase is the enzyme responsible for the methylation modification. 33
It catalyzes the transfer of a methyl group from the substrate S-adenosylmethionine
(SAM) to its substrates, which range from small molecules to proteins. SAM’s primary
role is donating a methyl group to different enzyme substrates. After the methyl group is
transferred,

SAM

is

converted

to

S-adenosylhomocysteine

(SAH).

So

far,

methyltransferases are thought to be the largest group of SAM-dependent enzymes
(Figure 4).33, 37
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S-adenosylhomocysteine
(SAH)

S-adenosylmethionine
(SAM)

Figure 4. Protein methylation catalyzed by methyltransferse.33

1.3.1 Bisubstrate kinetic mechanisms
Protein methyltransferases belong to bisubstrate enzymes since they need to
recognize both SAM and protein substrates. The kinetic mechanism of such bisubstrate
enzyme is defined as the sequence of events in that its substrates are bound and
products are released from the enzyme.40-42 A bisubstrate enzyme has two possible
mechanisms: a sequential (bi-bi) mechanism or a Ping-Pong mechanism.40,

41, 43

As

shown in Figure 5, in the sequential mechanism, both substrates “A” and “B” need to
bind to the enzyme; “E” firstly to form a ternary complex “EAB” to trigger the catalytic
activity of the enzyme. And both substrates will be converted into products “P” and “Q”,
and subsequently released from the enzyme.

7

Figure 5. Sequential (Bi-Bi) mechanism .

In the Ping-Pong mechanism, as shown in Figure 6, one of the substrate “A”
needs to bind to the enzyme “E” to “covalently” modify it, and it will be released as
product “P”. And this modified enzyme “F” will subsequently bind to another substrate “B”
to modify it and release it as product “Q”. After modification of substrates, “F” converts
back to its original form “E”.

Figure 6. Ping-pong mechanism.

Understanding a kinetic mechanism is crucial for enzyme characterization, as
well as inhibitor design. In order to determine the kinetic mechanism of a bisubstrate
enzyme, one of the most common methodologies is the Lineweaver-Burk double
reciprocal plot.41, 42

8

V: reaction rate
Vmax: maximum enzyme reaction rate
[S]: Substrate concentration
Km: substrate concentration that contributes to half Vmax
Figure 7. Lineweaver-Burk equation.

This equation is derived from Michaelis-Menten kinetics model as indicated in
Figure 7. Based on this equation, by plotting a graph of reaction rate reciprocal (1/V) vs.
substrate concentration reciprocal (1/[S]), a linear curve can be obtained with a slope of
Km/Vmax and its intersect at 1/Vmax on y-axis. If an enzyme is adopting a sequential bi-bi
mechanism, it should have an intersecting pattern as shown in Figure 8. Where, [A] and
[B] represent corresponding substrate concentrations. Each curve represents different
concentration of substrate B.

bi-bi mechanism

Ping-pong mechanism

Figure 8. Lineweaver-Burk plot of Bi-Bi and Ping-Pong mechanism.

9

In contrast, if the enzyme is adopting Ping-Pong mechanism, a parallel pattern
should be observed from the Lineweaver-Burk plot. 40-42

1.3.2 Protein arginine methyltransferases (PRMTs).
PRMTs methylate the guanidinium nitrogen of specific arginine residues on
histones (Figure 9).44, 45 According to the types of methylated arginine products, PRMTs
are divided into three subtypes. Type I PRMTs produce asymmetrically methylated dimethylarginine. And type II PRMTs produce symmetrically methylated di-methylarginine.
Type III PRMTs catalyze arginine mono-methylation.46 However, it is still unclear
whether the mono-methylated product is the final product or an intermediate subject to
further methylation.47 So far, eight PRMTs have been identified in humans: PRMT1,
PRMT3, PRMT4, PRMT6, PRMT8 belong to type I. And PRMT5, PRMT7 belong to type
II.46, 48
It is known that PRMTs are extensively involved in gene expression
regulation.44,

49, 50

Among PRMTs, PRMT1 is involved in mRNA biosynthesis and

heterochromatin formation. It also affects the subcellular localization of a number of its
substrates.44 Another noticeable member in this family is PRMT5, which regulates cell
cycle, transcription, differentiation, stem cells, spliceosome assembly, and so on.
Because of this, PRMT5 is an intriguing target for the study of different biological
mechanisms.51
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Figure 9. Protein arginine methylation.
Kinetic studies of PRMT1, PRMT5, and PRMT6 demonstrated that they all
follow a Bi-Bi mechanism, which indicates the binding of both substrates to form a
ternary complex.42, 43, 52 The gel-based activity methods were utilized in those studies,
which utilizing

14

C-labled SAM as the methyl donor. The incorporation of

14

C-labled

methyl group to the arginine residue of substrates is monitored by phosphorimager to
determine the rate of methylation.42, 43, 52

1.3.3 Protein lysine methyltransferases (PKMTs).
Site specific methylation of lysine on histone is regulated by a family of
enzymes called PKMTs (Figure 10).53 This family possesses a highly conserved SET
domain and is well-known as SET-domain protein methyltransferases.53-55 The SET
domain is composed of approximately 130 residues; it was discovered as a conserved
sequence in three Drosophila melanogaster proteins and was first characterized in
1998.56, 57 So far, seven families of SET proteins are identified – SET 1, SET 2, SUV 39,
EZ, RIZ, SMYD, and SUV4-20.57, 58 In addition to those family members described above,
there are a few orphan members, such as SET 7/9 and SET 8. 59
11

Although each PKMT has its specific roles, through methylating specific lysine
with specific methylation states, PKMTs are extensively involved in epigenetic
regulation

of

transcriptional

activation,

euchromatic/heterochromatic

silencing,

transcriptional elongation, and mitosis.60-65 However, their roles are not confined to
histone methylation; SET 7/9 was reported to methylate K189 of TAFF10, which is a
general transcriptional factor. Additionally, SET 7/9 was identified to be involved in
methylation of tumor suppressor p53, to increase its stability. Aberrant histone
methylation is linked to developmental disorders and diseases.59

Figure 10. Protein lysine methylation.
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1.4 Protein α-N-terminal methylation.
1.4.1 Discovery of α-N-terminal methylation
The first case of protein α-N-terminal methylation can be traced back to 1976
during a study of ribosomal subunits from E. coli.66-69 It was identified that several
ribosomal proteins; S11, L33 and L16, were methylated at their α-N-terminal amino
groups.67 Before 1987, different groups reported cases of N-terminal methylated
proteins of varied species.36,

70-72

Through sequence alignment of proteins that are

subject to α-N-terminal methylation, several unique features of this modification were
discovered. First, the first three amino acids at the N-termini of those proteins are
relatively conserved, thus suggesting that they may serve as a recognition site for
possibly enzymatic methylation. Second, the N-termini of prokaryotic and eukaryotic
proteins possess different sequences. According to their methylation states and Nterminal specificity, prokaryotic protein can be divided into two classes. One class is
those proteins subject to mono-methylation, which is comprised of ribosomal protein
L16, chemotaxis CheZ protein, ribosomal protein L33, and the translational initiation
factor IF-3. Those proteins were further divided into two subclasses based on their Nterminal sequences: L16 and CheZ possess glycine and proline at position 3 and 4,
respectively. In contrast, IF-3 and L33 have either methionine or alanine at the Nterminus which is followed by lysine and glycine. In addition, there are two ribosomal
protein subunits S11 and L11, they are also subject to N-terminal methylation. S11 has
a unique N-terminal sequence of Ala-Lys-Ala. And L11 was the only identified
prokaryotic protein that can be tri-methylated at that time, it has an N-terminal sequence
of Ala-Lys-Lys (Table 1).70
13

Table 1. N-terminal sequence of prokaryotic proteins that are subject to N-terminal
methylation.70

Protein

N-terminal sequence

L16
CheZ

Met - Leu - Gln - Pro Met - Met - Gln - Pro -

IF-3
L33

Met - Lys - Gly - Gly Ala - Lys - Gly - IIe -

S11
L11

Ala - Lys - Ala - Pro Ala - Lys - Lys - Val -

Compared to prokaryotic proteins that possess different N-terminal sequences
and methylation states, all identified eukaryotic proteins that can be N-terminally
methylated have a highly conserved N-terminal motif of Ala/Pro-Pro-Lys, and they all
can be mono-, di-, tri-methylated.70 At that time, the identified proteins that possess this
motif included myosin light chain LC-1, histone H2B, and cytochrome c-557. As most of
these proteins are part of macromolecular complexes, it is believed that N-terminal
methylation regulates protein-protein interaction. Since all of these proteins contain a
Pro-Lys motif at the second and third position of their N-termini, it was hypothesized that
a single enzyme named “PK methyltransferase” was able to recognize the unique Nterminal motif to methylate those proteins. Unfortunately, due to the limited technologies
and skills of that period, this “PK methyltransferase” was not identified. 70
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1.4.2 Discovery of protein N-terminal methyltransferase 1 & 2 (NTMT1/2)

In 2010 Webb et al. identified a protein named YBR261C/TAE1 that was
responsible for N-terminal methylation of proteins through profiling of ribosomal proteins
from yeast cells deficient in putative methyltransferases.73 YBR261C/TAE1 is conserved
across eukaryotes; its deletion strain showed abolished N-terminal methylation
capability. Along with the discovery of YBR261C/TAE1, two human homologues,
METTL11a and METTL11b were also identified.73 Both YBR261C/TAE1 and METTL11a
were demonstrated as active methyltransferases that recognize X-Pro-Lys N-terminal
sequence, where X can be alanine, proline and serine. A further investigation of enzyme
preference of the first residue of N-terminal sequence (X-Pro-Lys) suggests that those
enzymes can recognize a variety of amino acids at the first position, and among which
proline (Pro-Pro-Lys) had demonstrated the highest preference over other amino acids.
Furthermore, through investigating the effects of substituting the second and third
residues, it was found that both YBR261C/TAE1 and METTL11a prefer a Pro at position
2, and a Lys at position 3.74 This result is in agreement with a previous study that all
reported eukaryotic proteins subject to N-terminal methylation contain this motif.73

Interestingly, only three months after the first announcement of the
identification of NTMT1 in 2010, Schanar-Tooley et al. had published the discovery of
the first α-N-methyltransferase from Hela nuclear extracts and named it N-terminal
RCC1 methyltransferase (NRMT).75 NRMT is essentially the same enzyme discovered
by Webb et al.73 However, it is the first time that NRMT/NTMT1 was confirmed with
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ELISA as a methyltransferase responsible for RCC1 N-methylation. Multi-spindle
formation was observed during mitosis through knockdown of NRMT.75

Through docking studies and mutagenesis, only a few residues in the peptide
substrate binding site were suggested to be essential for enzyme catalytic activity. For
example, mutation of either residue N169 or D181 to lysine had abolished enzyme
activity. Additionally, through an N-terminal sequence search of GenBank, the SET
oncogene and Rb protein were identified as new substrates of NRMT/NTMT1. Both
proteins were later confirmed biologically as authentic substrates of NTMT1. As
mentioned before, the Rb protein is also known as the tumour suppressor, it is a
regulator of cell cycle, and identification of this protein for N-terminal methylation was of
great importance.75-77

A homologue named METTL11b was identified along with discovery of
NTMT1.73 However, a stable recombinant form of this protein was not obtained until
2013.

It

was

found

that

the

second

N-terminal

methyltransferase

named

NRMT2/NTMT2 has a similar localization as its homologue NTMT1, and recognizes the
same N-terminal motif of X-P-K. However, it was reported to be mainly a monomethylase as it only introduced one methyl group on its substrate. 78

1.4.3 NRMT/NTMT1 substrate specificity
Since the discovery of N-terminal methylation, it was believed that the second
residue of the NTMT1 substrates is always a highly conserved Pro (X-Pro-Lys).70
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However in 2012, Petkowski et al. reported that the proline at the second position can
be replaced by other residues: Ala, Glu, Met, Asn, Gln, Gly and Ser.79
In addition, Lys at position three had also been accepted as a highly conserved
residue because replacing this lysine by glutamine was reported to result in diminished
enzyme activity. Through testing the methylation of peptides with varied third residue,
Petkowski et al. demonstrated that arginine can also fit into this position. 79 This was
further confirmed when centromere protein A (CNEP-A) was identified as a new
substrate of NTMT1 in 2013.80, 81 It possesses a N-terminal sequence starting with GlyPro-Arg.81-83 This study suggests that NTMT1 has broader substrate specificity than
what was believed, and hence it was estimated that more than 300 proteins may be
subject to N-terminal methylation based on this expanded substrate recognition.81

1.4.4 Identification of new substrates of NTMT1.
1.4.4.1 Regulator of chromatin condensation 1 (RCC1)
The knowledge of these N-terminal methylation modifications were largely
uninvestigated until 2007, α-N-terminal methylation of a nucleotide - exchange factor
named RCC1 was reported.84 RCC1 is the only known guanine nucleotide exchange
factor for Ran GTPase, which plays indispensable roles in nucleo-cytoplasmic transport,
nuclear envelope assembly, and spindle formation in cell mitosis. 84-89 The association of
RCC1 with chromatin through binding with histone H2A and/or H2B regulated by Ran is
essential for RanGTP production (Figure 11).84, 90
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Figure 11. Diagram of RanGTP production.75

This is the first study that clearly demonstrated the function of N-terminal
methylation and showed that methylated RCC1 N-terminus is essential for its
association with chromatin, which in turn is crucial for cell mitosis. In order to examine
the essentiality of RCC1 N-terminal methylation regarding its binding to chromatin, a
series of RCC1 mutants were synthesized (APK-, PPK-, SPQ-, SPR-). Among them,
mutant SPQ- showed abolished N-terminal methylation, and it was subsequently used
for N-terminal methylation studies. Compared to wtRCC1, mutant RCC1 (SPQ-) with
defected N-terminal methylation showed decreased binding efficacy to chromatin, which
resulted in multi-spindle formation during mitosis. These results suggest the significance
of RCC1 N-terminal methylation in cell mitosis.84 The discovery of the significance of
RCC1 N-terminal methylation rebooted an interest in studies about protein N-terminal
methylation as well as providing the impetus for the discovery of NTMT1/NRMT1.
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1.4.4.2 Centromere protein (CENP)
CENP is a chromatin region that serves as a spindle attachment point. 80-82 It
plays essential roles in chromosome segregation during cell division. 90 CENP-B is a
highly conserved centromere component that facilitates centromere formation in
mammalian cells. It contains two important motifs: a DNA-binding motif at its N-terminus
that binds specifically to a 17-bp DNA motif called CENP-B box within centromeric αsatellite DNA, and a dimerization domain at its C-terminus.91, 92
The N-terminus of CENP-B, which is the DNA-binding motif, possesses a GlyPro-Lys sequence.80, 93-95 Hence it had been reasoned that CENP-B might be a new
substrate of NTMT1, which was confirmed in 2013 by Dai et al. that N-terminal
methylation of CENP-B by NTMT1 had strengthened its binding to centromeric DNA
(Figure 12).80

Figure 12. α-N-Terminal methylation of CENP-B.80
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Meanwhile, CENP-A was also identified as a new substrate of NTMT1. 95
CENP-A is highly conserved among eukaryotes, and it is essential for the assembly of
other centromeres. The function of N-terminal methylation of CENP-A remains elusive,
but CENP-A contains a unique N-terminal motif of Gly-Pro-Arg.91,

95

It had been

previously known that NTMT1 can recognize synthetic peptides that have different
amino acids at the first position and the third residue can be an Arg. However, CENP-A
and CENP-B are two natural substrates that possess Gly at the first position and Arg at
the third position (CENP-A).91 Considering the significance and roles of those two
proteins as histone variants in cell division, these discoveries again lit up the N-terminal
methylation field.

1.4.4.3 Discovery of damaged DNA-binding protein 2 (DDB2).

The UV-damaged DNA-binding protein complex (UV-DDB) is one of two
principal initiators of the nucleotide-excision repair (NER) pathway, which is responsible
for the repair of different type of DNA damages.96,

97

UV-DDB is a dimer complex

composed of two subunits: a 127 kDa protein DDB1 and a 48 kDa protein DDB2,
respectively. Through DDB2, UV-DDB binds specifically to the damaged site of DNA.
Mutation of DDB2 was shown to cause cancer prone diseases such as xeroderma
pigmentosum (XP).98, 99
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Figure 13. α-N-Terminal methylation of DDB2.98

DDB2 possesses an N-terminal motif of Ala-Pro-Lys, which suggested that
DDB2 might also be a substrate of NTMT1 (Figure 13).98 In 2014, through a LC-MS/MS
based assay, Cai et al. demonstrated that DDB2 is in fact a substrate of NTMT1, and
was mostly tri-methylated during the experiment. Moreover, DDB2 mutants with
defective N-terminal methylation had demonstrated diminished nuclear localization and
reduced recruitment to damaged DNA foci, suggested an indispensable role for DDB2
N-terminal methylation in UV-damaged DNA repair.98

1.4.5 NTMT1 bisubstrate inhibitors
The biological significance of NTMT1 in cell mitosis, damaged DNA repair, and
its upregulation in cancers has also motivated studies of NTMT1 inhibitor design. Kinetic
mechanism studies of PRMTs and PKMTs had illustrated that many members from this
family are adopting a sequential (Bi-Bi) mechanism, which requires the formation of a
ternary complex to initiate enzyme activity.52 As a member of the methyltransferse family,
we hypothesized that NTMT1 is likely to adopt this mechanism, and thus design and
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synthesize a bisubstrate inhibitor by covalently linking a SAM analogue with a peptide
substrate to mimic the ternary complex during enzyme catalysis. Such bisubstrate
inhibitors could simultaneously inhibit both binding sites to provide potent and specific
inhibitors.100 The bisubstrate inhibitor was designed by using N-adenosyl-L-methionine
(NAM) to mimic SAM, which processes a more stable nitrogen instead of a active
sulfonyl center. The N-terminal sequence derived from hRCC1 (SPKRIA) was used to
mimic the peptide substrate of NTMT1. The NAM and SPKRIA are linked through a
triazole linker based on our previous docking studies which shows that the sulfonyl
group and α-amino group of the peptide is about 3.6 Å (Figure 14).101

Figure 14. NTMT1 bisubstrate inhibitor.101

The designed bisubstrate inhibitor showed high inhibition potency (IC 50 = 0.81
+ 0.13 µM), which also demonstrating selectivity: our results indicate that it has less
than 15% inhibition effect on PRMT1 and less than 50% inhibition effect on G9a. This
molecule is the first designed bisubstrate inhibitor of NTMT1. 101
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1.5 Specific aims of this study
It has been forty years since the first identification of protein α-N-terminal
modification. In the meantime, the enzyme that is responsible for this type of
modification was identified as NRMT/NTMT1. Since discovery, its substrate specificity
has expanded from X-P-K (X = S, P, A) to X-P-K/R (X = S, P, A, G). Beside the natural
substrates, it was demonstrated that NTMT1 can also methylate different synthetic
peptides, e.g., where X can be most natural amino acids. Also, the conserved second
residue P can be replaced by other residues, although this observations somewhat
controversial.
Along with those discoveries, several new substrates of NTMT1 were also
identified. Among them, RCC1, Rb protein, oncoprotein SET, CENP-A/B and DDB2,
enhanced the significance of N-terminal methylation. Those substrates play critical roles
in chromatin segregation, cell cycle regulation, centromere formation, and UV-damaged
DNA repair, respectively.
However, studies of N-terminal methylation are still in an early stage. So far,
most studies about this modification have been focusing on its substrates’ function and
substrate specificity. In order to understand N-terminal modification in a better
perspective, it is important to obtain a comprehensive insight into the enzyme kinetics,
substrate specificity, mechanisms, and inhibition of NTMT1. Hence, the specific aims of
my graduate research are:
1. To develop biochemical assays to understand the kinetic mechanism of NTMT1.
2. To determine the mechanism of multi-step methylation progression by MALDI-MS
23

3. To elucidate the molecular basis of substrate recognition in a combination of crystal
structures, site-directed mutagenesis, biochemical assays and binding studies to
characterize the contribution of residues regarding substrate recognition.
4. To apply a combination of computational studies and biochemical assays to discover
small molecule inhibitors for NTMT1.
5. To understand the product specificity of NTMT1/2 through MALDI-MS base
methylation progression studies.
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2. Results and Discussion
2.1 Fluorescence assay development

2.1.1 Design

First, we need to establish a convenient and sensitive method to quantify
methylation in order to characterize the kinetic mechanism of NTMT1. We adapted a
fluorescence-based SAH hydrolase (SAHH)-coupled assay (Scheme 1), which monitors
the conversion of SAM to SAH, using SAHH to catalyze the quantitative hydrolysis of
SAH to adenosine and homocysteine (Hcy). Subsequently, the free thiol group of Hcy
reacts with a sulfhydryl-sensitive fluorophore called ThioGlo1 to form an Hcy-Thioglo1
adduct. This adduct has a strong fluorescence at 500 nm when it is excited at 370 nm.
The concentration of Hcy is subsequently determined by fluorescent intensity. In
essence, the rate of SAH production is measured during enzyme catalysis reactions in
this assay.

RCC1-12 peptide (SPKRIAKRRSPP) derived from the N-terminus of RCC1 and
showed exothermic binding to NTMT1 with a Kd = 70 µM, was used this RCC1-12 as
the NTMT1 substrate in the fluorescence-based assay. It was synthesized using
standard Fmoc chemistry on an automated peptide synthesizer and purified by reverse
phase. A correct mass of RCC1-12 (exact mass: 1390.8633) was confirmed via a
MALDI-MS.
25

Scheme 1. Schematic diagram of fluorescence-based assay mechanism.
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2.1.2 Assay optimization and validation

The correlation study between fluorescence intensity and free thiol concentration

Figure 15. Standard curve of fluorescence intensity vs. [GSH].
Since the fluorescence intensity is our readout of the assay, the first thing was
to ensure measured fluorescence intensity is proportional to product concentration. We
used the commercially available glutathione (GSH) that contains a free thiol group to
titrate the fluorescence intensity. The concentration range of GSH from 0 to 3 μM was
examined in this study. We used excess amount of ThioGlo1 (15 μM) to ensure that
ThioGlo1 is not a limiting factor. A standard curve of fluorescence intensity vs. GSH
concentration was plotted in Microsoft Excel (Figure 15) and our results indicated that
GSH concentration and measured fluorescence intensity is in linear relationship with R 2
= 0.9997.
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Comparison of fluorescent dyes

To investigate the sensitivity of the fluorescent dye, we compared two
commonly used fluorophores: ThioGlo1 and CPM. Both dyes are specific to free thiol
groups. The difference is that CPM-thiol adduct generates a strong fluorescence at 480
nm. Under a similar condition as described above, we found the formations of thiol
adduct with both ThioGlo1 and CPM is linear with respect to the GSH concentration. As
shown in Figure 16, ThioGlo1 is more sensitive to free thiol with a larger slope.
Therefore, we chose ThioGlo1 for the following studies.

Figure 16. ThioGlo1 vs. CPM.
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Time-dependent studies

For this study, NTMT1 (0.2 µM) was incubated in the reaction buffer containing
25 mM Tris, 50 mM KCl, pH 7.5, 15 µM ThioGlo1, 10 µM SAHH, 100 µM SAM, and 100
µM RCC1-12 at 37 °C. The concentration of formed product SAH during the reaction
was derived from a standard calibration curve generated with glutathione and ThioGlo1.
The result of this study indicated a linear relationship between product formation and
reaction time during 12 minutes (R2 = 0.9919) (Figure 17). 10 µM SAHH was used to
ensure that the hydrolysis of SAH was not rate-limiting as compared to NTMT1 catalysis.

Figure 17. Time dependent studies.41
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Concentration dependent studies

Figure 18. Concentration dependent studies.41

In order to determine enzyme concentration and activity linearity range,
concentration-dependent studies were conducted in the reaction buffer containing 25
mM Tris buffer, 50 mM KCl, pH 7.5, 15 µM ThioGlo1, 10 µM SAHH, 100 µM SAM, and
100 µM RCC1-12 at 37 °C. Initial velocity was analyzed using a time frame within 10%
turnover using Microsoft Excel. Our result showed that the NTMT1 concentration is in
linear relationships with reaction rates ranging from 0 to 0.4 μM (R2 = 0.9996. This result
suggests that any enzyme concentration within this range should follow an enzyme
concentration-activity linearity relationship. It was decided to use 0.2 μM as the assay
concentration for NTMT1 kinetic studies, since it gave a better signal to background
ratio (Figure 18).
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Km determination of SAM and RCC1-12

Figure 19. Km Studies of SAM and peptide substrate RCC1-12.41
The steady state kinetic parameters were determined for both RCC1-12 and
SAM using our continuous fluorescence assay. As Km values of SAM for most protein
methyltransferases are around 10 µM, we used 100 µM SAM that was assumed to be at
a saturated concentration to determine the Km value of RCC1-12. Various
concentrations (0-40 µM) of RCC1-12 peptide were incubated with the reaction mixture
and fluorescence was monitored for 12 min. The Km of RCC1-12 was determined as 4.9
+ 0.7 μM. Likewise, we used 50 µM of RCC1-12 peptide in the presence of various
concentration of SAM (0-100 µM) to determine the Km of SAM, which was 8.0 + 1.6 μM
(Figure 19).
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2.2 Bisubstrate kinetic mechanism characterization

2.2.1 Design

The data for the initial rates of RCC1-10 peptide were determined at different
fixed concentrations of the SAM (12.5, 25, 50, 100 µM). For reactions where the SAM
was the varied substrate, the initial rates were examined at fixed concentration of
RCC1-10 peptide (1, 2, 4, and 8 µM). The initial rates were globally fit to the following
equations using least squares nonlinear regression with GraphPad Prism 5 software.41

When A is saturating, αKB = KmB

KA and KB are the dissociation constants of the substrate A and B bind to the free
enzyme, respectively. Vmax and Km are the Michaelis constants.41

2.2.2 Lineweaver-Burk double reciprocal plots
Table 2. Initial velocity studies.41
varied
substrate
RCC1-10
SAM
a

fixed
substrate
SAMa
RCC1-10

b

kcat (min-1)

K(RCC1) (µM)

Km(RCC1) (µM)

0.59±0.03

3.3±1.3

1.6±0.4

1.36±0.09

2.3±0.4

b

[SAM] = 12.5, 25, 50, or 100 µM. [RCC1-10] = 1, 2, 4, or 8 µM.
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K(SAM) (µM)

Km(SAM) (µM)
13.6±2.8

7.85±2.93

6.1±1.7

Km(RCC1-10), Km(SAM), K(RCC1-10) values were obtained when the concentration of
RCC1-10 peptide was varied at different fixed concentrations of the SAM. Similar ly,
Km(RCC1-10), Km(SAM), and K(SAM) values were obtained when the concentration of SAM
was varied at different fixed concentrations of the RCC1-10 (Table 2). The resulting
double reciprocal plots exhibit an increasing slope with decreasing SAM and RCC1-10
concentrations respectively, producing intersecting lines with the intercept lying in the
second quadrant (Figure 20).41 This pattern indicates that NTMT1 catalysis proceeds in
a sequential bi-bi mechanism. Therefore, NTMT1 requires formation of a ternary
complex for the initiation of catalytic reaction, which further confirms our rationale of
design for bisubstrate inhibitors.

Figure 20. Lineweaver-Burk plot of 1/v vs. 1/[RCC1-10] and 1/v vs. 1/[SAM].41
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2.3 NTMT1 methylation progression studies

2.3.1 Design

As discussed previously, substrates of NTMT1 have different methylation
states (mono-, di-, and tri-), but it was unknown how di-, or tri-methylation were
achieved. If substrates are methylated from the unmethylated state to tri-methylated
state in a single step, the methylation progression is following a “processive”
mechanism. If substrates were methylated stepwise and intermediates were released
during the enzyme catalysis, it is following a “distributive” fashion (Figure 21).

Figure 21. Methylation progression patterns of NTMT1.41
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2.3.2 Methylation progression studies via MALDI-MS

In order to unveil the methylation progression pattern of NTMT1, Dr. Stacie
Richardson from our lab has developed a direct ratiometric quantification, matrixassisted laser desorption/ionization (MALDI)-MS assay to directly measure substrate
concentrations of the varied methylation states.41 Following this method, Dr. Richardson
monitored concentration of different intermediates at different time points ( Figure 22).
The total concentration of RCC1 used in this experiment was 10 μM. By utilizing the

concentration of the RCC1 as an internal standard, and comparing the relative
monoisotopic peak areas, we were able to measure the populations of all methylation
states simultaneously.

Methylation progression profiles indicate that both Me-RCC1 and Me2-RCC1 had
reached 50% of the total substrate population.41 Thus, 5~6 μM of Me-RCC1 and Me2RCC1 were detected at different time points during the methylation progression. Since
only 0.2 μM of NTMT1 was used in this assay, 5~6 μM of intermediates suggested that
intermediates released from NTMT1 are accumulating in the reaction mixture, and
subsequently rebound to NTMT1 for further methylation. Overall, the result of
methylation progression assay suggests that NTMT1 follows a distributive methylation
mechanism. However, a full-length protein substrate may exhibit a processive
mechanism if it has significantly higher affinity to the enzyme or a slower off-rate than
the enzyme turn-over time. Future study with full-length protein substrates would be
interesting to explore this possibility.41
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Figure 22. Methylation progression profiles of NTMT1.41
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2.4 Effects of peptides’ length, methylation states, and sequences on substrate
binding and recognition

2.4.1 Design
NTMT1 is known to methylate proteins that contain an X-Pro-Lys motif.70 So far,
peptides substrates used for NTMT1 kinetic studies were derived from the first twelve or
ten residues of N-terminus of RCC1 since these were reported to have a binding affinity
of 10 μM for NTMT1.79 However, contributions of length, methylation states, and key
residues of NTMT1 substrates are still elusive. In order to understand the effects of
peptide length regarding enzyme kinetics, we synthesized peptides of varied length
(RCC1-6, RCC1-9, RCC1-10 and RCC1-12).

On the other hand, our methylation progression studies suggested that the
mechanism of NTMT1 methylation is distributive.41 It is worth noting that upon each step
of methylation, the N-terminus of substrate is sterically changed. So, we prepared
peptides with varied methylation states to explore how methylation would affect
substrate binding and recognition. To address this question, peptides of varied
methylation state were synthesized: RCC1-10, MeRCC1-10, and Me2RCC1-10. Kinetic
studies were carried out on these to determine the kinetic parameters of each peptide.

In order to investigate the contribution and define the specificity of the first
residue of the recognition motif (X-Pro-Lys), we chose positively charged Arg,
negatively charged Asp, polar aromatic Tyr, and the nonpolar hydrophobic residues Trp
and Lys at the first position. Steady state kinetic studies were carried out to determine

37

the Km, kcat, and kcat/Km values of each peptide. ITC analysis was utilized by our
collaborator (Dr. Min’s lab) to directly analyze their binding affinities.

The second residue Pro at the N-terminus is highly conserved. To understand
contributions of Pro regarding substrate binding and recognition, Dr. Min’s lab has
designed peptides of varied second residues including I, Q, E, and S.

2.4.2 Peptide length effect
Table 3. Kinetic studies of peptide substrates of varied length.41
Peptide ID
RCC1-6
RCC1-9
RCC1-10
RCC1-12

Sequence
SPKRIA
SPKRIAKRR
SPKRIAKRRS
SPKRIAKRRSPP

K m (μM)
3.2
1.4
0.89
3.1

+ 0.4
+ 0.1
+ 0.09
+ 0.3

k cat (min-1)
0.56
0.53
0.44
0.57

+ 0.02
+ 0.01
+ 0.01
+ 0.01

k cat/Km (M-1 min-1)
1.8 x 105
3.8 x 105
4.9 x 105
1.8 x 105

The results of peptides’ length studies are summarized in Table 3. Kinetic
studies on peptides with different lengths (6-12 mer) gave Km values from 0.81 to 4.72
µM and kcat values from 0.43 to 0.61 min-1. The kcat/Km values ranged from 1.78×105 to
4.93×105 M-1 min-1. Among these four peptides, RCC1-10 has the lowest Km of 0.89 +
0.09 μM, which suggests that a C-terminal residue to the Ser-Pro-Lys motif also
contributes to substrate recognition. In comparison, all peptides of different lengths
exhibited similar kcats, which suggests NTMT1 can efficiently catalyze a hexapeptide.
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2.4.3 Methylation state effect
Table 4. Kinetic studies of peptide substrates of varied methylation state.41

Peptide ID
RCC1-10
MeRCC1-10
Me2RCC1-10

Sequence
SPKRIAKRRS
Me-SPKRIAKRRS
Me2-SPKRIAKRRS

K m (μM)

k cat (min-1)

k cat/Km (M-1 min-1)

0.89 + 0.09
1.4 + 0.1
4.3 + 0.5

0.44 + 0.01
0.58 + 0.01
0.59 + 0.02

4.9 x 105
4.1 x 105
1.4 x 105

Since RCC1-10 exhibited the lowest Km (Table 3), this peptide was chosen for
the studies of methylation effects (Table 4). RCC1-10, MeRCC1-10, and Me2RCC1-10
represent three different methylation states. The kinetic studies indicated that
unmethylated

(RCC1-10)

and

mono-methylated

(MeRCC1-10)

peptides

have

comparable Kms of 0.89 μM and 1.4 μM, respectively. In contrast, di-methylated peptide
has a four-fold increased Km compared to the unmethylated peptide, which suggests
that NTMT1 can bind and catalyze unmethylated and mono-methylated RCC1-10 in a
similar fashion. But the di-methylated peptide may have introduced steric factors to an
extent that affects substrate binding.

While comparing kcat of each peptides, it suggests that di-methylated RCC1-10
has comparable turnover numbers compared to unmethylated and mono-methylated
peptide, which further proved our hypothesis that varied methylation state can
significantly affect substrate binding, yet NTMT1 can still efficiently catalyse peptides of
different methylation state.
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2.4.4 Effects of the first residue

As the hexapeptide was shown to be efficiently methylated by NTMT1 in our
previous study, our collaborator (Dr. Min’s lab) prepared a series of hexapeptides to
investigate the contribution and the tolerability of the first residue of the N-terminus:
SPKRIA (hRCC1), PPKRIA (mRCC1), RPKRIA (positively charged), YPKRIA (polar
aromatic), WPKRIA (non-polar hydrophobic), LPKRIA (non-polar hydrophobic), and
DPKRIA (negatively charged).
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Figure 23. Steady state kinetic profiles of peptides with varied first residue. 102

41

Table 5. Steady state kinetic studies of peptides with varied first residue.102

(ND) No detectable activity at 250 μM peptide and a saturating amount of SAM.

Steady state kinetic profiles of each peptides substrate are presented in
Figure 23. Results of kinetic studies of these peptides with different first residues are
summarized in Table 5. As indicated, despite the fact that the only structural variation of
these peptides is the sidechain of the first residue, their Km values span from 0.3 µM
(PPKRIA) to 126 µM (WPKRIA). Compared to SPKRIA (Km = 7.9 + 0.7 μM), both
RPKRIA and YPKRIA have 2 ~ 4 fold lower Kms of 4.0 + 0.5 μM and 1.6 + 0.3 μM,
respectively. This is in agreement with previous reported studies that the first residue
can be positively charged due to the extensively negatively charged substrate binding
site (see Appendix).79 A positively charged residue like arginine is electronically
favorable. In addition, from our crystal structure, there is a spacious pocket by the
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sidechain of the first residue, the size of which can accommodate an aromatic ring such
as tyrosine.102

In comparison, the non-polar hydrophobic peptides WPKRIA and LPKRIA have
significantly increased Kms of 126 + 7 μM and 54 + 6 μM, respectively, which suggests
that the substrate binding site of the first residue is unfavorable with respect to nonpolar hydrophobic residues. Lastly, the negatively charged peptide DPKRIA did not
show any sign of methylation; this is in agreement with a previous study that negatively
charged binding site tend to dispel negatively charged residues. 79
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Figure 24. ITC analysis of peptides with varied first residues.102
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LPKRIA

Results of ITC analysis are in agreement with that of the kinetic studies.
PPKRIA shows the best binding with Kd = 189 nM. RPKRIA (Kd = 3.7 uM) and YPKRIA
(Kd = 4.1 µM) have about three folds lower Kd values compared to SPKRIA (Kd = 14 µM).
Both hydrophobic residues WPKRIA (Kd = 47 µM) and LPKRIA (Kd = 48 µM) have 3-fold
increased Kd compared to SPKRIA. Negatively charged DPKRIA did not show any sign
of binding (Figure 24).

Interestingly, a bimodal binding was observed from the ITC profiles of some
peptides (Figure 24).102 This is especially evident for those peptides with high binding
affinities, such as PPKRIA, RPKTIA, and YPKRIA. We hypothesized that it may be
attributed to the possibility that NTMT1 purified from E. coli contains endogenous SAM,
which could consequently methylate peptides during ITC analysis. Co-purification of
endogenous SAM along with methyltransferase has been documented before. 103
Therefore, the observed bimodal binding is resulted from a mixture of methylated and
unmethylated substrates with their varied binding affinities for NTMT1. In order to test
our hypothesis, the MALDI-MS based assay was carried out without external addition of
SAM. As mentioned before, N-terminal methylation of a substrate requires the formation
of a ternary complex of NTMT1–peptide–SAM. If NTMT1 used in the experiment does
not contain SAM, no methylation should be observed, and vice versa.
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Figure 25. MALDI-MS spectra of S/P/Y/RPKRIA.102

Results of MALDI-MS based study are shown in Figure 25. Spectra that are
named by peptide sequences are controls with peptides alone, from which only [M + H] +
and [M + Na]+ peaks are observed. However, spectra labelled with peptide sequence
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plus NTMT1 contain [M + Me + H]+ peaks. Peptide with high binding affinity such as
PPKRIA even contains the [M + 2Me]+ peak. The above results from MALDI–MS based
assay supports our hypothesis that NTMT1 used in the experiment contains a certain
amount of endogenous SAM, which causes the bimodal binding phenomenon observed
from ITC analysis studies.102

2.4.5 Effects of the second residue

Four peptides of varied second residues were synthesized: SIKRIA, SQKRIA,
SEKRIA, SSKRIA. Kinetic studies were carried out to determine their kinetic parameters.
Table 6. Steady state kinetic study results of peptides with varied second residues.102

(ND) No detectable activity at 250 μM peptide and a saturating amount of SAM.

As summarized in Table 6, after replacement of the second Pro by IIe, Gln, Glu,
and Ser, no methylation could be detected from fluorescence assay. Results from ITC
analysis are consistent with results from kinetic studies, which are shown in Figure 26.
Both kinetic studies and ITC analysis suggested that Pro2 is essential as the binding
abilities of all four peptides are completely abolished. Previously reported substrate
specificity studies of NTMT1 stated that the second residue Pro can be replaced by Ala,
Glu, Met, Asn, Gln, Gly and Ser through in vitro peptide methylation assays and
substrate immunoprecipitations.79 However, our studies were the first quantitative
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measurement of various peptide substrates and results supported the dogma of X-ProLys motif.102
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Figure 26. ITC analysis of peptides with varied second residues.102
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2.5 Structural basis study for substrate binding and recognition

2.5.1 Design

New co-crystal structures of NTMT1 in complex with SAH and two different
hexapeptide substrates including the human (hRCC1-6: SPKRIA) and mouse RCC1
(mRCC1-6: PPKRIA) were successfully obtained by Dr. Jinrong Min’s lab at the
Structural Genomics Consortium.102 These crystal structures reveal that its substrate
peptides are inserted into a negatively charged channel of NTMT1 (see Appendix),
which is in striking contrast to that of other protein methyltransferases (see Appendix).
We identified a few key residues (N168, W136, D180 and D177) that contribute to the
substrate recognition and performed site-directed mutagenesis studies to elucidate the
interactions (Figure 27).102

SPKRIA

RPKRIA

YPKRIA

Figure 27. NTMT1–SAH–R/Y/SPKRIA ternary complex.102

2.5.2 Kinetic studies of NTMT1 mutants

The carboxamide group of the side chain of Asn168 interacts with the
backbone carbonyl group of Ser (Figure 27). To examine the contribution of Asn168,
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site-directed mutagenesis was carried out to replace Asn168 with a Lys. The results of
kinetic studies that characterized through the fluorescence assay (Table 7) have
demonstrated that N168K has ~36-fold higher of Km and two-fold lower of kcat than
wtNTMT1.102 Therefore, this mutation has affected not only substrate binding and
recognition, but also enzyme catalytic activity.

Trp136 was identified as having a stacking interaction with the sidechain of
Pro2. After mutation of Trp136 to Phe, the kinetic parameters dramatically decreased
with Km > 200 μM and kcat > 0.04 + 0.01 min-1 (Table 7). Meanwhile, mutant of Trp136 to
Ile has undetectable enzyme activity. Both mutants suggest the importance of the
stacking interaction between side chains of Pro2 and Trp136.102
Table 7. Steady state kinetic studies of NTMT1 mutants.102

-1

-1

-1

Enzyme

K m (μM)

k cat (min )

k cat/K m (μM min )

Wide type

7.3 + 0.7

0.10 + 0.01

1.4 x 10-2

N168K
W136F
W136I
D180K
D180Y

263 + 141
>200
ND
ND
ND

0.05 + 0.01
>0.04 + 0.01
ND
ND
ND

1.9 x 10-4
/
ND
ND
ND

(ND) No detectable activity at 250 μM peptide and a saturating amount of SAM.

To examine the essentiality of the two interactions between Lys3 and
Asp180/Asp177 (Figure 27), site directed mutagenesis was carried out to mutate both
residues. Those mutations were expected to disrupt these electrostatic interactions. Our
results from kinetic studies indicate that neither D180K nor D180Y have detectable
methylation activity (Table 7). While integrating this result with the ITC analysis that
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performed by our collaborator, Dr. Min’s lab (Figure 28), it can be seen that the peptide
substrate (SPKRIA) is not able to bind to either D180K or D180A, which further
confirmed that the interaction between Asp180 and Lys3 is essential in terms of
substrate binding. On the other hand, compared to wtNTMT1 (Kd =14 µM), D177A has
about two-fold increased Kd (32 µM), which is an indication of the decreased binding
affinity after interrupting the interaction between Asp177 and Lys3. 102
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Figure 28. ITC analysis of mutants D180A, D180K and D177A.102
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2.6 Discovery of a small molecule inhibitor for NTMT1

2.6.1 Design

Specific chemical probes that modulate methylation have functioned as
valuable chemical tools to investigate NTMT1-mediated biological processes. Our lab
developed the first potent and specific NTMT1 bisubstrate inhibitor that displays an IC 50
of 0.8 µM for NTMT1 and is more than 60-fold selective over protein lysine
methyltransferase G9a and arginine methyltransferase 1.101 The bisubstrate inhibitors
offered us a valuable probe for biochemical studies of NTMT1, but have limited use in
biological studies due to their low stability in the presence of serum in cell culture media.
While we continue our efforts to optimize structures of our bisubstrate inhibitors,
discovery of novel small molecule inhibitors for NTMT1 will be critical for the
interrogation of the biological functions of NTMT1 and elucidatation of the different
responses to knockdown of NTMT1 in normal and transformed cells.
We used the only available (at that time) X-ray crystal structure for the human
NTMT1 protein in complex with product SAH (PDB ID: 2ex4, 1.75 Å) to predict the
substrate binding site and develop the initial search query in collaboration with the Dr.
Glen Kellogg’s lab. Our goal was to discover small molecule inhibitors that target the
binding site of the peptide substrate; thus, the active site was defined by the cavity
opposite the SAH binding site. The flow chart of this study is illustrated in Figure 29.
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Figure 29. Project plan for discovery of small molecule inhibitors.
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2.6.2 Computational studies
We defined the query based on several features surrounding the pocket,
including one aromatic site (Trp136), two acceptor sites (Asp177, Asp180), and one
donor site (Asn168). The NTMT1 structure, including the SAH, was processed in SybylX 1.1 by deleting all water molecules, adding all protons and performing an energy
minimization of these protons while holding the heavy atoms as an aggregate. Initial
virtual screening was performed with the UNITY module of Sybyl against the open NCI
database of 250,000 unique compounds. The resulting 150 UNITY hits were then
docked with GOLD 5.1 and the highest scoring poses were then energy minimized and
rescored with HINT. These 150 promising leads were ranked based on HINT score and
were visually inspected. We requested from the NCI these high-ranking compounds for
primary screening with the fluorescence-based assay.
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2.6.3 Biochemical screening with recombinant NTMT1
Single dose inhibitory activity studies

Figure 30. Results of 100 μM primary screening.

We aim to identify selective small molecule inhibitors that target the unique
peptide substrate binding site of NTMT1, so we used an excess amount of SAM (100
µM) and substrate peptide RCC1-12 peptide at its Km value of 5 µM in the screening.
The reaction was allowed at 37 oC for 10 min with or without the addition of inhibitors .
Obtained compounds were subject to single dose screening. 100 μM was used as the
final inhibitor concentration. Results of single dose screening are shown in Figure 30.
Compound NCI657593 was identified exhibiting over 85% inhibition in 100 μM. The
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resulting top five compounds were chosen (NCI657593, NCI51367, NCI610742,
NCI48774, and NCI73559) for subsequent studies.

Secondary assays to remove false positives

Figure 31. Secondary screening to remove false positive.
This experiment was conducted in order to exclude possibilities of false results.
If an inhibitor is targeting SAHH, increasing SAHH concentration should show reduced
inhibitory activity. Results from Figure 31 indicate that after doubled SAHH
concentration, none of our compounds showed drastic changes in terms of inhibitory
activity, and this suggests that their activity is not from SAHH inhibition.
Occasionally, introduction of a compound to the assay can result in protein
aggregation. Aggregated enzymes normally have no enzymatic activity, which also
leads to false inhibition results. Triton is a detergent commonly used in biochemical
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assay to prevent protein aggregation. Through addition of triton, if the inhibitory activity
of a compound is caused by aggregation, it would show reduced inhibitory activity. Our
results indicate that NCI48774 showed significant reduced inhibitory activity after 0.04%
of triton was added, which implies that this compound might introduce protein
aggregation, and its inhibitory result is not reliable.
IC50 studies
Table 8. IC50 studies.

IC50 is an important indicator of the potency of an inhibitor. In this study a threetime serial dilution of each sample was carried out with DMSO. The inhibitory activities
of compounds in different concentrations were monitored through fluorescence assay.
The results of IC50 study indicate NCI657593 has the lowest IC50 of 7.4 + 0.6 µM. Other
compounds have at least >70 µM IC50 (Table 8).
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Selectivity study
Table 9. Selectivity study.

Compound

NTMT1

IC50 (µM)
PRMT1

NCI657593

7.4 + 0.6 µM

>50 µM

G9a
>50 µM

Inhibitor selectivity was determined by comparing IC50 values of the inhibitor
with other methyltransferases; e.g. PRMT1 and G9a. As shown in Table 9, compared to
NTMT1, compound NCI657593 has >50 µM IC50 for both arginine methyltransferases
PRMT1 and lysine methyltransferase G9a, which suggests that it is selective for NTMT1
among these three methyltransferases.
Similarity search
Table 10. Inhibitory activity and IC50 studies of NCI657593 analogues.
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Since NCI657593 showed extraordinary inhibitory activity, compounds that are
structurally similar to NCI657593 were ordered. Subsequently, 100 µM single dose
inhibition study and IC50 studies were conducted to examine their inhibitory activity.
However, results indicate that all compounds possess >70 µM IC 50 (Table 10). Even
though NCI657593 was identified as a small molecule with significant inhibitory activity
and selectivity, the molecular structure of NCI657593 remains to be validated through
synthesis or further characterization.
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2.7 Substrate specificity and methylation progression studies of NTMT1/NTMT2
2.7.1 Project design
Along with the discovery of NTMT1 (METTL11A), a homologue named
METTL11B (NTMT2) was also identified.81 NTMT2 recognizes the same N-terminal
motif of X-P-K/R, and possesses N-terminal methylation activity.85 Structurally, NTMT2
has about 50% sequence identity and 75% sequence similarity with NTMT1 (Figure 32).
Those residues that were identified crucial for substrate binding and recognition in the
substrate binding site (Trp136, Asn168, Asp177, Asp180) are also conserved in
NTMT2.85 In addition, it has similar cellular localization and tissue expression pattern as
NTMT1. However, as described previously, NTMT2 was reported as a monomethylase
to prime the substrates of NTMT1 to facilitate further methylation of substrates by
NTMT1.

Figure 32. Sequence alignment of NTMT1 and NTMT2.
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The goal of this study is to analyze substrate and product specificity of NTMT1
and NTMT2 to understand the role and function of NTMT2 and its relationship with
NTMT1. Due to the low activity of NTMT2, we were not able to characterize the kinetic
parameters through fluorescence assay. Hence we used a MALDI-MS based assay to
monitor methylation progression for substrates of varied first residues with NTMT1 and
NTMT2 in parallel.

2.7.2 Methylation progression studies
Table 11. Methylation progression study results summary.
Peptide
SPKRIA
Sme1PKRIA

Mono-methylation
YES/YES

NTMT1/NTMT2
Di-methylation Tri-methylation
YES/NO
NO/NO
YES/NO
YES/NO

PPKRIA
Pme1PKRIA
YPKRIA
RPKRIA
WPKRIA

YES/YES

YES/NO

YES/YES
YES/YES
YES/YES

YES/NO
YES/NO
YES/NO

YES/YES
NO/NO
NO/NO
NO/NO

DPKRIA
QPKRIA
NPKRIA
LPKRIA
GPRRRS
GPKRRQ

NO/NO
YES/YES

NO/NO
YES/NO

NO/NO
NO/NO

YES/YES
YES/YES
YES/YES
YES/YES

YES/NO
YES/NO
YES/YES
YES/YES

NO/NO
NO/NO
YES/YES
YES/YES

The results of these methylation progression studies of NTMT1 and NTMT2
are summarized in Table 11. The remaining mass spectra of the other peptides are
attached in Appendix (Figure 1 ~ Figure 26). As shown, both NTMT1 and NTMT2 can
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monomethylate most peptides except DPKRIA. From our previous studies, DPKRIA
shows no binding to NTMT1, probably because the negatively charged aspartic acid is
considered unfavorable for similarly negatively charged substrate binding site.
The difference between both enzymes starts to show at the di-methylation step.
It indicates that, except peptides GPKRRQ and GPRRRS (and DPKRIA), all peptides
can be di-methylated by NTMT1. However, none of them achieved di-methylation
through NTMT2. It is also worth noting that from time-dependent methylation
progression studies, NTMT2 showed an apparent slower methylation rate than NTMT1.
Therefore, the di-methylation incapability of NTMT2 is whether due to its slower
methylation rate, or another intrinsic mechanism remains to be discovered.
On the other hand, our results indicate that peptides with high binding affinity
such as GPKRRQ, GPRRRS, and MePPKRIA had illustrated full methylation (trimethylation of GPKRRQ, GPRRRS, and di-methylation of Me-PPKRIA) by both
enzymes.
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3. Conclusions
We have characterized the kinetic mechanism of recombinant NTMT1 using a
fluorescence assay and mass spectrometry. The results of studying the initial velocity
indicate that methylation by NTMT1 proceeds via a random sequential bi-bi mechanism,
which implicates that both SAM and peptide substrate need to bind to NTMT1 to form a
ternary complex to initiate enzymatic reaction. This mechanism supports our rationales
of designing bisubstrate inhibitors that mimic the ternary complex during enzyme
catalysis. Thus compound could simultaneously inhibit both binding sites. In addition,
our processivity studies demonstrate that NTMT1 proceeds via a distributive
mechanism for multiple methylations. Our processivity studies had indicated the
existence of mono- and di-methylated substrates of significant concentrations while
enzyme catalysis reactions, which indirectly suggests that both mono- and dimethylated substrate play roles in the biological system.
The results of peptides’ length, methylation states, and sequence on substrate
recognition showed that hexapeptides gave comparable Km and kcat values. The Km
studies for peptides with varied N-terminal residues defined that NTMT1 can recognize
a motif X-P-K/R, where X can be any amino acid except D/E. Newly identified substrates
like centromere H3 variants (CENP-A/B) supported this expanded consensus. We also
determined that conserved residues N168, W136, D117, and D188 are critical for
substrate binding. These results along with the results from substrate specificity studies
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had provided valuable information in terms of substrate binding and recognition in
structural basis, which lay a solid foundation for designing of highly selective
peptidomimetic and/or small molecule inhibitors in the future.
In the meantime, we utilized computational studies and fluorescence assays to
discover a small molecule inhibitor that targets the substrate binding site of NTMT1. We
identified one compound that exhibits potent inhibitory activity with an IC 50 value of 7.4 +
0.6 µM. Moreover, this compound showed selectivity for NTMT1 compared with PRMT1
and G9a. Even through the molecular structure of this compound remains to be
validated, however it is the first non-substrate analogue inhibitor identified so far for
NTMT1. It can be used as a lead for inhibitor design.
Lastly, our results suggest that NTMT2 is able to di- and tri-methylate those
substrate peptides that have high binding affinity to NTMT1/2, such as GPKRRQ,
GPRRRS, and PPKRIA (MePPKRIA). However, most peptides that can be dimethylated by NTMT1 were not being able to di-methylated by NTMT2. Our studies
confirmed that NTMT2 can monomethylate all NTMT1 substrates. Furthermore, we
discovered that it is capable of di-, tri-methylate some substrates with high binding
affinity, which implies that NTMT2 is not a monomethylase.
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4. Future direction

Even though the N-terminal methylation modification has been known for a
long time, it began to stimulate increasing interest after the discovery of NTMT1 in 2010.
Studies about this modification and its enzymes are still at very early stage. In our study,
we have demonstrated that NTMT1 is adopting Bi-Bi mechanism while catalysis
reaction and its substrates are methylated in a distributive fashion. Our structural basis
study indicated a few important residues in substrate binding site and refined its
substrate motif to X-P-K/R, where X can be any amino acid except D/E. However, there
remains little explanation for the high binding affinity of peptides with X = Pro (PPKRIA),
which is derived from mouse RCC1. Also the catalytic mechanism of NTMT1 still needs
to be further elucidated. Structural characterization of our identified small molecule
inhibitor remains to be clarified.

Compared to NTMT1, NTMT2 is a newly identified N-methyltransferse. It was
reported as a monomethylase that plays a role to prime the substrates of NTMT1 to
facilitate further methylation of substrates by NTMT1. However, our methylation
progression assay indicates that NTMT2 is capable of di- and tri-methylation of some
peptides that have high binding affinity to NTMT2. Future studies are needed to
understand whether this is due to substrate specificity or the methylation rate difference
between the two homologues.
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Protein α-N-terminal methylation plays an important role in regulating proteinDNA interactions, mitotic division and DNA damage repair; however, little is known
about the biological functions of this modification. Therefore, identification of proteins
that recognize and bind to N-terminal methylated proteins would advance our
understanding of its biological functions.
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5. Experimental and methods
5.1 Materials and instruments

SAM, ThioGlo1, Tris, KCl, NaCl, TECP, NH4H2PO4, TFA, dimethylformamide,
α-Cyano-3-hydroxycinnamic acid, amino acids, and other chemicals and reagents were
purchased from VWR, Fischer, Aldrich, EMD, Caliochem and Chemlmpex. NTMT1 (AD003) clone was purchased from Addgene. SAHH clone was obtained from Dr. Raymond
C. Trievel through a Materials Transfer Agreement.
Flexstation3 Multi-Mode Microplate Reader was utilized for NTMT1 kinetic
characterization. And methylation progression assay was carried out via an Applied
Biosystems Voyager matrix-assisted laser desorption/ionization time-of-flight mass
spectrometer.

5.2 NTMT1 purification
NTMT1 preparation for kinetic studies
His-NTMT1 was expressed in E. coli BL21 (DE3) codon plus RIL cells in
Terrific Broth medium in the presence of 50 g/mL kanamycin, using a pET28a-LIC
expression vector that encodes a full-length NTMT1 (aminoacids1–222) with His6 tag
obtained from Addgene. Cells were grown at 37 °C to A600 of 1.5, induced by isopropyl
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β-D-1-thiogalactopyranoside (final concentration 1 mM), and incubated overnight at
15 °C. Cells were harvested by centrifugation at 5,000 rpm. Cell pellets were suspended
in the lysis buffer containing 25 mM Tris-HCl buffer (pH 8.0) containing 300 mM NaCl
and 10 mM imidazole, lysed by passing through a Microfluidizer (MicrofluidicsCorp.) at
20,000 p.s.i., and centrifuged at 15,000 rpm for 15 min at 4 °C. The supernatant was
loaded on to a nickel-nitrilotriacetic acid agarose column. After removal of unbound
protein by extensive washing with the lysis buffer, the protein was eluted with 25 mM
Tris-HCl buffer (pH 8.0) containing 100 mM imidazole and 300 mM NaCl. Combined
elution fractions were dialyzed in the dialysis buffer (25 mM Tris, pH7.5, 150 mM NaCl,
50 mM KCl) three times to provide His-NTMT1. The yield was 20 mg/L.

NTMT1 preparation for crystal structure and mutagenesis
The gene of human NTMT1 (2-223) was amplified and cloned into a modified
pET28a-LIC vector to express NTMT1 with a 6 His-tag and a thrombin cleavage site at
the N-terminus. The recombinant NTMT1 plasmid was transformed into E. coli BL21
(DE3) codon plus RIL strain for induced expression with 0.2 mM IPTG at 16 °C
overnight. NTMT1 was purified by Ni2+-affinity and anion-exchange chromatography,
followed by further purification through Superdex™ 200 10/300 (GE Healthcare). The
buffer for gel filtration contained 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM TECP.
The peak fractions were collected and concentrated to 37 mg/mL for crystallization
assay. The mutant proteins were purified using the same procedure as described above.
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5.3 Peptide preparation
hRCC1-6 (SPKRIA, [M+H]+ = 670.4359), hRCC1-9 (SPKRIAKRR, [M+H]+ =
1110.7331), hRCC1-10 (SPKRIAKRRS, [M+H]+ = 1197.7651), and hRCC1-12
(SPKRIAKRRSPP, [M+H]+ = 1392.8546) were synthesized on Rink amide resin using
standard Fmoc chemistry with a CEM Liberty microwave peptide synthesizer. Fmoc
protection groups at the α-N-termini were removed by 20% (v/v) piperidine in N,Ndimethylformamide. MeRCC1-10 was synthesized based on literature.103 The Me2RCC1-10 peptide was synthesized as follows. To the deprotected RCC1-10 peptide on
resin (0.1 mmol) in N,N-dimethylformamide (2 mL) was added formaldehyde (24 µL of
37% (w/v) solution, 0.24 mmol), HOAc (20 µL), and NaBH3CN (15 mg, 0.24 mmol). The
mixture was placed on a shaker for 4 h. The resin was washed with N,Ndimethylformamide, and the reaction was repeated.

5.4 Fluorescence intensity vs. [GSH] correlation study
A three-fold serial dilution of GSH (0~30 μM) with 1x buffer solution (25 mM
Tris-HCl, pH 7.5, 50 mM KCl) was conducted. The reaction was initiated by addition of
10 μL of GSH solution in different concentration to each well of 96-well microplate
containing 10 μL of 10x reaction buffer (250 mM Tris-HCl, pH 7.5, 500 mM KCl), 1 μL
ThioGlo1 (1.5 mM stock solution in DMSO) and 79 μL ddH2O. Subsequently, 96-well
microplate with testing sample was placed into FlexStation 3 microplate reader preset at
37 °C. The program was set as: kinetics, fluorescence bottom read, excitation of 370
nm, emission of 500 nm, duration 15 min with measurements at 15 seconds intervals.
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After the fluorescence intensity was measured, the obtained raw data was processed to
make a plot of Relative Fluorescence Units (RFU) as a function of GSH concentrations
in Microsoft Office Excel scatter plot. The value for R2 was calculated after linear
regression.

5.5 Time-dependent studies
A reaction mixture of 0.2 μM NTMT1, 10 μM SAHH, 100 μM SAM, and 15 μM
ThioGlo1 in buffer (25 mM Tris, 50 mM KCl, pH = 7.5) was premixed (90 µL in total) and
transferred to a well of 96-well microplate. The reaction was initiated with 10 μL of 50
μM RCC1-10, and incubated in the FlexStation 3 at 37 °C for 5 min. The program of
FlexStation 3 was set as: kinetics, fluorescence bottom read, excitation of 370 nm,
emission of 500 nm, duration 15 min with measurements at 15 seconds intervals. And
the reaction was monitored continuously for 15 min. The obtained RFU was converted
to [SAH] using the standard curve obtained (RFU vs. [GSH]). Then, data was processed
to make a plot of [SAH] as a function of time as a Microsoft Office Excel scatter plot.
The value for R2 was calculated after linear regression.

5.6 Concentration-dependent studies
A reaction mixture of 10 μM SAHH, 100 μM SAM, and 15 μM ThioGlo1 in 1x
buffer solution (25 mM Tris-HCl, pH 7.5, 50 mM KCl) was premixed (89 µL in total) and
transferred to each well of a 96-well microplate. NTMT1 was diluted with 1x buffer in
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different concentrations: 40 µM, 30 µM, 20 µM, 10 µM, 5 µM. 1 µL of NTMT1 solution at
varied concentration was added into the above reaction mixture. The reaction was next
initiated with 10 μL of 50 μM of RCC1-10, incubated under 37 °C for 5 min, and
monitored by the FlexStation3 microplate reader (kinetics, fluorescence bottom read,
excitation of 370 nm, emission of 500 nm, duration 15 min with measurements at 15
seconds intervals). The obtained RFU was converted to [SAH] using the standard curve
obtained (RFU vs. [GSH]). Then, data was processed to make a plot of [SAH] as a
function of time in Microsoft Office Excel scatter plot. Initial rates were calculated and
processed to make a plot of rate as a function of [NTMT1]. Then, data was processed to
make a plot of [SAH] as a function of time as a Microsoft Office Excel scatter plot.

5.7 Steady state kinetic characterization of NTMT1 substrates
5.7.1 SAM
Serial dilution of SAM was carried out to a final concentration range (100 µM, 50 µM, 25
µM, 12.5 µM, 6.3 µM, 3.1 µM, 1.6 µM). A reaction mixture of 0.2 μM NTMT1, 10 μM
SAHH, SAM, and 15 μM ThioGlo1 was premixed in the 1x reaction buffer (25 mM Tris,
50 mM KCl, pH 7.5) and 90 µL was transferred to each well of 96-well microplate and
incubated at 37 °C for 5 min. The reaction was next initiated with 10 μL of 50 μM of
RCC1-12, incubated under 37 °C for 5 min, and monitored by the FlexStation3
microplate reader (kinetics, fluorescence bottom read, excitation of 370 nm, emission of
500 nm, duration 15 min with measurements at 15 seconds intervals). The obtained
data were processed as described before and subsequently fit into Michaelis-Menten
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model using least square nonlinear regression regression with GraphPad Prism 5
(Version 5.04).
5.7.2 Peptide substrates
Each peptide was diluted to 10 mM using deionized water. Serial dilution was
carried out to a final concentration range (64 µM, 32 µM, 16 µM, 8 µM, 4 µM, 2 µM, 1
µM, 0.5 µM, 0). A test run was carried out following the fluorescence assay as
described previously to estimate the concentration range for kinetics studies. Based on
the results of these test runs, specific serial dilutions tailored for each peptide were
adjusted.
A reaction mixture of 0.2 μM NTMT1, 10 μM SAHH, 100 μM SAM, and 15 μM
ThioGlo1 was premixed in the 1x reaction buffer (25 mM Tris, 50 mM KCl, pH 7.5) and
90 µL was transferred to each well of 96-well microplate and incubated at 37 °C for 5
min. The reaction was next initiated with addition of varied concentrations of RCC1-12
in different wells and monitored by the FlexStation3 microplate reader for 15 min. The
result was processed by Microsoft Office Excel scatter plot. The obtained data were
processed as described before and subsequently fit into Michaelis-Menten model using
least square nonlinear regression regression with GraphPad Prism 5 (Version 5.04).

5.8 NTMT1 kinetic mechanism characterization
RCC1-10 was prepared in varied concentrations (20 μM, 10 μM, 5 μM, 2.5 μM,
1.25 μM, 0.625 μM) through serial dilution with deionized water. Four kinetic
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experiments with varied SAM concentration (12.5 μM, 25 μM, 50 μM, 100 μM) were
carried out in parallel. The detailed experimental procedures were as described above.
Obtained initial velocities from each experiment were globally fitted into LineweaverBurk kinetic equation using least square nonlinear regression GraphPad Prism 5
software (Version 5.04).
For the SAM binding site, SAM was prepared in varied concentration (51.2 μM,
25.6 μM, 12.8 μM, 6.4 μM, 3.2 μM, 1.6 μM) through serial dilution with deionized water.
Different RCC1-10 concentrations (1 μM, 2 μM, 4 μM, 8 μM) were used for each
experiment. Similarly, the obtained initial velocity from each experiment was globally fit
with the Lineweaver-Burk kinetic equation using least square nonlinear regression
GraphPad Prism 5 software (Version 5.04).

5.9 MALDI-MS methylation progression study

NTMT1 methylation progression studies
The reaction buffer (20 mM Tris, 50 mM KCl, pH 7.5), RCC1-10 (10 μM), and
NTMT1 (0.2 μM) were premixed, and incubated in a 30 °C water bath for 5 min. After
incubation, the reaction was initiated by addition of 50 μM SAM. The reaction took 2
hours. Every 20 min, a 3 μL sample was withdrawn from the reaction mixture, and
quenched in 1:1 ratio using quenching solution (20 mM NH4H2PO4, 0.4% (v/v) TFA, in
1:1 ACN/water). 1 μL quenched samples were spotted onto MALDI plate along with αCyano-3-hydroxycinnamic acid, and examined by MALDI-MS.
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Methylation progression studies of peptides of varied first residue with NTMT1 and
NTMT2
A 36 µL reaction mixture was prepared, which is composed of: 2 µL NTMT1/2
(40 µM), 30 µL reaction buffer (20 µM Tris, 50 µM NaCl, pH = 7.5), and 4 µL peptide
substrate (200 µM). This reaction mixture was incubated in 30 °C water bath for 5
minutes, and initiated with 4 µL SAM (400 µM). At each time point (0 min, 15 min, 30
min, 60 min, 120 min, overnight), 3 µL of reaction mixture was withdrawn and quenched
in 1:1 ratio by quenching solution (20 mM NH4H2PO4, 0.4% (v/v) TFA, in 1:1 ACN/water).
Quenched

samples were

spotted

onto

MALDI plate

along

with

α-cyano-3-

hydroxycinnamic acid, and examined by MALDI-MS.
MALDI-MS based study of endogenous SAM
Buffer (20 mM Tris-HCl, 150 mM NaCl, pH 7.5) was mixed with 50 μM SAM
and 1 mM peptide (SPKRIA, PPKRIA, RPKRIA, YPKRIA). Reaction mixtures were
incubated at 30 °C for 2 h. After 2 h, the testing samples were withdrawn from each
reaction mixtures were subsequently quenched in 1:1 ratio by the quenching solution
(20 mM NH4H2PO4, 0.4% (v/v) TFA, in 1:1 ACN/water). These quenched samples were
spotted onto a MALDI plate along with α-Cyano-3-hydroxycinnamic acid, and examined
by MALDI-MS.
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5.10 Virtual screening and docking studies
By using the NTMT1 – SAH binary complex (PDB ID: 2EX4, 1.75Å) crystal
structure model, a query was designed based on the predicted interactions between
substrate and NTMT1. An aromatic region was defined complementary to Trp137. And
a hydrophobic region was defined in the center of Val218, Leu211, and Ile37. The acid
side chain of Asp181 was defined as an acceptor atom. Finally, a negative center was
defined (surrounded by Asp181, Asp178, Asp168, and Ser163). Subsequently, a virtual
screening was carried out by using designed query. Libraries used for virtual screening
include NCI, Asinex, Chembridge, Maybridge, Otava, and SigmaAldric. In total, there
were around 2,500,000 compounds were surveyed.
Hits obtained from virtual screening were docked into both binding sites of
NTMT1. Results were shown as scores using HINT (Hydropathic INTeractions) score
functions. Both SAM and peptide binding sites were scored. Docking scores of SAM
binding site was used as a reference to compare with those of the peptide binding site.
Molecules with high scores at the peptide binding site, and low scores at the SAM
binding site were expected. This observation suggests that such hits have higher
possibilities of targeting the peptide binding site.
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5.11 Biochemical screening of small molecule compounds
5.11.1 Primary screening using SAHH-coupled fluorescence assay
The samples to be tested were diluted and prepared as 10 mM stock solutions
in 1.5 mL amber vials. 1 μL (10 mM) of each sample was added into each well of
microplate. Subsequently, 90 μL of reaction mixture was prepare for each well of a 96well microplate. The reaction mixture is composed of 0.2 μM NTMT1, reaction buffer (20
mM Tris, 50 mM KCl, pH 7.5), 10 μM SAHH, 100 μM SAM (10 x Km concentration) and
15 μM ThioGlo1. Reactions were initiated with 10 μL (50 μM) (1 x Km concentration) of
RCC1-10, and measured by the FlexStation3 microplate reader. The obtained raw data
were processed by Microsoft Office Excel in scatter plots.

5.11.2 Secondary screening to remove false positive
Four parallel inhibition assays of each candidate were carried out, preparation
procedure and methodology were as described previously. The first and second
experiments have varied SAHH concentrations, 1 x SAHH and 2 x SAHH respectively.
And the third and fourth experiments have 0.01% and 0.04% of triton. The obtained
data were processed by Microsoft Office Excel in scatter plots.
5.11.3 IC50 studies
Three-fold serial dilution of each sample was carried out with DMSO, and 1 μL
of each sample in different concentrations were added into a 96-well microplate.
Reaction mixtures were prepared as described previously, and the reaction was initiated
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with 10 uL (50 μM) RCC1-10, incubated under 37 °C, and read by FlexStation3
microplate reader. The obtained data was firstly processed by Microsoft Office Excel in
scatter plots; and IC50 profiles were determined through SigmaPlot 5 using “response vs.
Log conc.” of non-linear regression.

5.11.4 Selectivity studies
IC50 studies were conducted as described previously with NTMT1, PRMT5, and
G9a, respectively. Obtained data were processed by Microsoft Office Excel in scatter
plots, and the IC50 profiles were determined through SigmaPlot 5 “response vs. Log
conc.” of non-linear regression.
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Appendix
Table 1. Molecular mass of peptides of varied methylation states
Mass
M+H
M+Na
M+K
M+Me+H
M+Me+Na
M+Me+K
M+2Me+H
M+2Me+Na
M+2Me+K
M+3Me
Mass
M+H
M+Na
M+K
M+Me+H
M+Me+Na
M+Me+K
M+2Me+H
M+2Me+Na
M+2Me+K
M+3Me

SPKRIA
671
693
709
685
707
723
699
721
737
683

PPKRIA
681
703
719
695
717
733
709

YPKRIA
747
769
785
761
783
799
775
797
813
789

RPKRIA
740
762
778
754
776
792
768
790
806
782

DPKRIA
699
721
737
713
735
751
727
749
765
741

WPKRIA
770
792
808

QPKRIA
712
734
750

GPKRRQ
740
762
778

GPRRRS
727
749
765

LPKRIA
697
719
735

NPKRIA
698
720
736

784
806
822
798
820
836
812

726
748
764
740
762
778
754

754
776
792
768
790
806
782

741
763
779
755
777
793
769

711
733
749
725
747
763
739

712
734
750
726
748
764
740
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Figure 1. Methylation progression of PPKRIA with NTMT1.
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Figure 2. Methylation progression of PPKRIA with NTMT2.
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Figure 3. Methylation progression of GPKRRQ with NTMT1.
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Figure 4. Methylation progression of GPKRRQ with NTMT2.
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Figure 5. Methylation progression of GPRRRS with NTMT1.
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Figure 6. Methylation progression of GPRRRS with NTMT2.
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Figure 7. Methylation progression of SPKRIA with NTMT1.
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Figure 8. Methylation progression of SPKRIA with NTMT2.
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Figure 9. Methylation progression of MeSPKRIA with NTMT1.
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Figure 10. Methylation progression of MeSPKRIA with NTMT2.
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Figure 11. Methylation progression of RPKRIA with NTMT1.
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Figure 12. Methylation progression of RPKRIA with NTMT2.
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Figure 13. Methylation progression of YPKRIA with NTMT1.
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Figure 14. Methylation progression of YPKRIA with NTMT2.
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Figure 15. Methylation progression of QPKRIA with NTMT1.
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Figure 16. Methylation progression of QPKRIA with NTMT2.
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Figure 17. Methylation progression of DPKRIA with NTMT1.
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Figure 18. Methylation progression of DPKRIA with NTMT2.

105

WPKRIA – NTMT1
0 min

60 min

15 min

120 min

Overnight

30 min

Figure 19. Methylation progression of WPKRIA with NTMT1.
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Figure 20. Methylation progression of WPKRIA with NTMT2.
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Figure 21. Methylation progression of LPKRIA with NTMT1.
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Figure 22. Methylation progression of LPKRIA with NTMT2.
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Figure 23. Methylation progression of NPKRIA with NTMT1.
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Figure 24. Methylation progression of NPKRIA with NTMT2.
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Figure 25. Methylation progression of MePPKRIA with NTMT1.
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Figure 26. Methylation progression of MePPKRIA with NTMT2.
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Figure 27. Peptide substrate binding sites of NTMT1 and PRMT5.
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